Sage Therapeutics Inc [NASDAQ: SAGE] closed the trading session at $9.07.
The stocks have a year to date performance of 67.03 percent and weekly performance of 33.19 percent. The stock has been moved at 53.99 percent over the last six months. The stock has performed 37.22 percent around the most recent 30 days and changed 13.09 percent over the most recent 3-months.
If compared to the average trading volume of 968.09K shares, SAGE reached to a volume of 27419767 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Sage Therapeutics Inc [SAGE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SAGE shares is $8.93 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SAGE stock is a recommendation set at 2.88. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Sage Therapeutics Inc shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on March 11, 2025. The new note on the price target was released on November 21, 2024, representing the official price target for Sage Therapeutics Inc stock. On October 04, 2024, analysts decreased their price target for SAGE shares from 10 to 4.
The Average True Range (ATR) for Sage Therapeutics Inc is set at 0.44, with the Price to Sales ratio for SAGE stock in the period of the last 12 months amounting to 11.98. The Price to Book ratio for the last quarter was 1.38, with the Price to Cash per share for the same quarter was set at 6.77.
SAGE stock trade performance evaluation
Sage Therapeutics Inc [SAGE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 33.19. With this latest performance, SAGE shares gained by 37.22% in over the last four-week period, additionally plugging by 53.99% over the last 6 months – not to mention a drop of -16.41% in the past year of trading.
Sage Therapeutics Inc [SAGE]: An insightful look at the core fundamentals
Sage Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.13 and a Current Ratio set at 9.13.
Earnings per share (EPS) analysis for Sage Therapeutics Inc [SAGE] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SAGE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sage Therapeutics Inc go to 35.78%.
Sage Therapeutics Inc [SAGE]: Institutional Ownership
The top three institutional holders of SAGE stocks are: VANGUARD GROUP INC with ownership of 6.42 million shares, which is approximately 10.5988%. FMR LLC, holding 5.82 million shares of the stock with an approximate value of $$63.24 million in SAGE stocks shares; and FMR LLC, currently with $$59.52 million in SAGE stock with ownership which is approximately 9.0531%.
